<DOC>
	<DOCNO>NCT02975349</DOCNO>
	<brief_summary>The aim protocol find safety effectiveness M2951 patient relapse multiple sclerosis . Patients place 1 3 group receive M2951 , placebo tecfidera 24 week . After 24 week , patient placebo give M2951 .</brief_summary>
	<brief_title>A Study Efficacy Safety M2951 Subjects With Relapsing Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Subjects diagnosis relapse multiple sclerosis ( may include subject Secondary Progressive Multiple Sclerosis ( SPMS ) superimpose relapse provide meet criterion ) accordance revise McDonald criterion MS Lublin Reingold Male female age 18 65 year One document relapse within 2 year Screening either : ) One relapse occur within last year prior randomization b ) presence least 1 Gd+ T1 lesion within 6 month prior randomization would make patient eligible . Expanded Disability Status Scale score 0 6 Baseline Women childbearing potential must use supplementary barrier method together highly effective method contraception ( accord International Council Harmonisation [ ICH ] guidance M3 [ R2 ] ) 4 week prior randomization , throughout trial , 90 day last dose IMP . Signed date informed consent ( subject must able understand inform consent ) indicate subject inform pertinent aspects trial prior enrolment comply requirement protocol . Progressive MS Disease duration &gt; 15 year subject EDSS 2 less Use following , determine protocol ; rituximab , ocrelizumab , mitoxantrone , lymphocytedepleting therapy , lymphocyte trafficking blocker ( eg , natalizumab , fingolimod ) , intravenous ( IV ) immunoglobulins ( Ig ) , plasmapheresis , immunosuppressive treatment , Binterferons glatiramer acetate , Systemic glucocorticoid , teriflunomide Exposure Tecfidera within 6 month prior randomization Any allergy , contraindication , inability tolerate Tecfidera Treatment dalfampridine ( fampridine , Ampyra ) unless stable dose ≥ 30 day prior randomization Inability comply MRI scan Immunologic disorder MS , exception secondary wellcontrolled diabetes thyroid disorder , condition require oral , IV , intramuscular , intraarticular corticosteroid therapy Vaccination live liveattenuated virus vaccine within 1 month prior Screening Severe drug allergy history anaphylaxis , allergy IMP incipients Active , clinically significant viral , bacterial , fungal infection , major episode infection require hospitalization treatment parenteral antiinfectives within 4 week Screening , completion oral antiinfectives within 2 week Screening , history recurrent infection ( ie , 3 type infection 12month rolling period ) . Vaginal candidiasis , onychomycosis , genital oral herpes simplex virus consider Investigator sufficiently control would exclusionary . History positive test human immunodeficiency virus ( HIV ) , hepatitis C ( HCV ) antibody and/or polymerase chain reaction , hepatitis B surface antigen ( HBsAg ) ( + ) and/or hepatitis B core total , and/or immunoglobulin M ( IgM ) antibody ( + ) Screening . The subject : • Has history current diagnosis active tuberculosis ( TB ) • Is currently undergoing treatment latent TB infection ( LTBI ) • Has untreated LTBI • Has positive QuantiFERON®TB test Screening . Indeterminate QuantiFERON® Subjects current household contact active TB also exclude History splenectomy major surgery within 2 month prior Screening History myocardial infarction cerebrovascular event per protocol History attempt suicide within 6 month prior Screening positive response item 4 5 ColumbiaSuicide Severity Rating Scale ( CSSRS ) An episode major depression within last 6 month prior Screening On anticoagulation , fish oil supplement , antiplatelet therapy daily aspirin cardioprotection treatment Tecfidera induce flush History cancer , except adequately treat basal cell squamous cell carcinoma skin Breastfeeding/lactating pregnant woman Participation investigational drug trial within 1 month 5 halflives investigational drug , whichever long , prior Screening Subjects currently receive ( unable stop use prior receive first dose IMP ) medication herbal supplement know potent inhibitor cytochrome P450 3A ( CYP3A ) History current alcohol substance abuse Clinically significant abnormality electrocardiogram screen chest Xray Clinically significant laboratory abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>M2951</keyword>
	<keyword>Relapsing Multiple Sclerosis</keyword>
	<keyword>Bruton 's Tyrosine Kinase inhibitor</keyword>
</DOC>